AVRO RD 04

Drug Profile

AVRO RD 04

Alternative Names: Cystinosis gene therapy - AVROBIO

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenStem Therapeutics
  • Developer AVROBIO
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cystinosis

Most Recent Events

  • 04 Oct 2017 AVROBIO announces intention to submit IND application to the US FDA for Phase-I/II trial in Cystinosis in late 2017
  • 04 Oct 2017 AVROBIO in-licenses Cystinosis gene therapy from GenStem Therapeutics
  • 04 Oct 2017 AVROBIO plans a clinical trial for Cystinosis in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top